免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
晚期黑色素瘤中治疗前情绪困扰与 TIL（肿瘤浸润淋巴细胞）治疗反应之间的关联
英文原题：The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma.
查看英文原题
The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们的研究结果表明，TIL 治疗前 ED 升高与治疗结局降低相关，凸显了进一步研究应激-免疫-癌症轴的必要性。
研究思路结论见上方概要
目的
采用TIL（肿瘤浸润淋巴细胞）（TILs）的过继细胞治疗（ACT）已显示对一线免疫检查点抑制剂（ICIs）难治的晚期黑色素瘤患者有益。然而，TIL治疗反应的预测性生物标志物有限。临床前研究表明，情绪困扰（ED）可能损害抗肿瘤免疫反应。我们对III期TIL试验（NCT02278887）进行了事后分析，以评估治疗前ED与TIL治疗结局之间的关联。
方法
ED 使用由 Impact of Event Scale 和 EORTC QLQ-C15-PAL 的情绪功能子量表得出的复合评分进行评估。采用中位数分割法将患者分为 ED 升高组（n = 32）或 ED 正常组（n = 40）。为评估所得结果是否依赖于 ED 分类方法，进行了敏感性分析，以比较复合 ED 评分处于最低三分位数（ED 正常，n = 26）和最高三分位数（ED 升高，n = 25）的患者之间的 TIL 治疗结局。
结果
ED升高与客观缓解率降低（37% vs. 69%；校正比值比，0.28；95%置信区间[CI]，0.19-0.75；P = 0.013）以及1年（31% vs. 58%）和2年（16% vs. 35%；校正风险比，1.84；95% CI，1.03-3.26；P = 0.038）无进展生存率下降相关。使用三分位分组法的敏感性分析显示类似趋势（比值比，0.35；95% CI，0.11-1.08，P = 0.072）。
展开英文摘要原文
METHODS
ED was evaluated using a composite score derived from the Impact of Event Scale and the emotional functioning subscale of the EORTC QLQ-C15-PAL. Patients were stratified into elevated ED (n = 32) or normal ED (n = 40) groups using a median split approach. To evaluate whether the obtained results were dependent on the ED classification method, a sensitivity analysis was conducted to compare TIL therapy outcomes between patients with composite ED scores in the lowest tertile (normal ED, n = 26) and highest tertile (elevated ED, n = 25).
RESULTS
Elevated ED was associated with a reduced objective response rate (37 % vs. 69 %; adjusted odds ratio, 0.28; 95 % confidence interval [CI], 0.19-0.75; P = 0.013) and decreased progression-free survival rates at 1-year (31 % vs. 58 %) and 2-years (16 % vs. 35 %; adjusted hazard ratio, 1.84; 95 % CI, 1.03-3.26; P = 0.038). Sensitivity analysis using the tertile grouping method showed a similar trend (odds ratio, 0.35; 95 % CI, 0.11-1.08, P = 0.072).
CONCLUSION
Our findings suggest that elevated ED before TIL therapy is associated with reduced therapeutic outcomes, underscoring the need for further investigation into the stress-immune-cancer axis.
论文信息
- 作者
- Egeler MD、Klobuch S、Tak WS、Rohaan MW、Borch TH、Noringriis IM、Tissier R、Lucas MW
- 单位
- Department of Psychosocial Oncology and Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: m.egeler@nki.nl.Netherlands
- 文献类型
- III 期临床试验 · 随机对照试验
- 期刊
- European journal of cancer (Oxford, England : 1990)2025 Sep 9
- 原文标识
- PubMed 40674829 · DOI 10.1016/j.ejca.2025.115640